Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gottlieb On Being Senate-Confirmed US FDA Commissioner: It's Certainly An Advantage

Executive Summary

US FDA would have more influence in inter-agency turf battles, can build stronger relationships on Capitol Hill with a confirmed commissioner, Scott Gottlieb says.

You may also be interested in...



Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA

Commissioner Scott Gottlieb will leave FDA less than two years after his confirmation, but will exit with a substantial list of accomplishments for industry and patients.

US FDA Creates Expedited Review For Military-Related Products

All 'top priority' battlefield products will get FDA review by June 30; longer term plan includes draft guidance on development of products designed for use in austere conditions.

Battlefield Emergency Use Bill Faces Pushback From US FDA, Authorizing Committees

Top Republicans on FDA authorizing committees worry that undermining agency's sole authority to approve drugs and devices would bring more harm than good.

Topics

UsernamePublicRestriction

Register

PS141010

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel